Silo Pharma Advances PTSD Drug with Robustness Study Ahead of FDA Meeting
Event summary
- Silo Pharma engaged Resyca to conduct a robustness study for its SPC-15 PTSD therapeutic, evaluating the microchip-based nasal spray system.
- The study aims to assess device performance consistency and formulation stability over a 30-day period ahead of a planned FDA Type C meeting request.
- SPC-15 is designed for nose-to-brain delivery, potentially increasing drug concentrations in the brain while reducing systemic exposure.
- Silo previously aligned with the FDA on the streamlined 505(b)(2) regulatory pathway for SPC-15 approval.
The big picture
Silo Pharma's advancement of its SPC-15 PTSD therapeutic underscores the strategic importance of targeted drug delivery systems in addressing underserved psychiatric conditions. The company's focus on nose-to-brain delivery aligns with broader industry trends toward improving drug efficacy and safety profiles for CNS diseases. The upcoming FDA Type C meeting will be critical in determining the regulatory pathway forward.
What we're watching
- Regulatory Strategy
- How the FDA Type C meeting will shape Silo's IND strategy and Phase 1 clinical trial design.
- Execution Risk
- Whether Silo can successfully demonstrate consistent device performance and formulation stability in the robustness study.
- Market Dynamics
- The pace at which Silo can advance SPC-15 through clinical development given the competitive landscape for PTSD therapeutics.